Independent Midbrain Gene Therapy Study by Kebilidi

NCT02852213 is not the pivotal trial for Kebilidi (eladocagene exuparvovec-tneq) approval but an investigator-initiated Phase 1 study of AAV2-hAADC. Led by Professor Krystof Bankiewicz from The Ohio State University and supported by the U.S. National Institutes of Health (NIH), this open-label, single-arm dose-escalation trial began in 2016 and is currently recruiting. The target enrollment is 42 pediatric patients, with an estimated completion date of July 2031 and long-term follow-up until March 2037. Equating the preliminary results of the first 7 patients to the commercial success of PTC Therapeutics (PTCT)'s Kebilidi may overestimate the development stage and product value.

Restoration of Dopamine Circuits via Substantia Nigra and Ventral Tegmental Area Injection

AAV2-hAADC is a candidate that expresses the human aromatic L-amino acid decarboxylase (AADC) enzyme using an adeno-associated virus 2 vector. It is delivered bilaterally to the compact part of the substantia nigra (SNc) and the ventral tegmental area (VTA) via magnetic resonance imaging-guided convection-enhanced delivery (CED). This anatomical strategy differs from Kebilidi, which is injected into the striatal putamen. The initial cohort included 3 patients at 1.3×10^11 vector genomes and 4 patients at 4.2×10^11 vector genomes, with target coverage rates of 98% and 70% in the substantia nigra and VTA, respectively. The key differentiator is the use of midbrain dopamine neurons and axonal transport to restore AADC activity across a broader circuit.

Initial Data from 7 Patients Show Efficacy Signals and Limitations

Data from 7 patients aged 4–9 years, published in 2021, showed that the surgery and vector administration were generally well-tolerated, with increased dopamine metabolites and FDOPA uptake in all patients. Oculogyric crises were completely resolved in 6 of 7 patients within 3 months, and 6 patients achieved normal head control at 12 months, with 4 achieving independent sitting. At 18 months, 2 patients reached bilateral supported walking, but these results from a small Phase 1 trial without a control group do not imply confirmatory comparative efficacy. The death of one patient was attributed to underlying disease 7 months post-surgery, and long-term safety and sustained developmental benefits are key endpoints for the expanded cohort.

Approved Products and Chinese Pipeline Set Competitive Benchmarks

PTC's Kebilidi delivers the DDC gene to the putamen via an AAV2 vector and received FDA accelerated approval for adult and pediatric AADC deficiency on November 13, 2024. It is marketed as Upstaza in Europe since July 2022 for patients aged 18 months and older with severe disease. PTC's Upstaza and Kebilidi sales reached USD 56.626 million in 2025, up from USD 16.913 million in 2024. Current standard treatments include dopamine agonists like pramipexole and ropinirole, monoamine oxidase inhibitors like selegiline, and vitamin B6 with symptomatic therapy, but none address the root cause of the disease. China's Shanghai Vitalgen BioPharma is also developing an AAV9-based candidate, VGN-R09b, in early Phase 1 trials NCT05765981 and a Phase 1 dose-escalation and confirmation trial NCT06432140, creating a competitive landscape based on vector and delivery site strategies.

Commercial Success Depends More on Delivery Systems Than Clinical Differentiation

AADC deficiency is an ultra-rare disease, so market penetration is determined more by diagnostic rates, access to specialized neurosurgery centers, and insurance coverage than by patient numbers. Kebilidi's 2025 sales represent the most direct indicator of the actual global commercial market size. Midbrain-injected candidates must demonstrate superior motor and behavioral outcomes or surgical efficiency compared to the approved putamen-injected product. The current trial is still in the recruitment phase of Phase 1, not an approved stage, so it is not yet appropriate to link it to the enterprise value or sales of an independent product. However, if the initial 7 patients' motor gains and safety profile are replicated in the expanded 42-patient cohort, it could provide important comparative data for central nervous system gene therapy target selection and CED platform design.